The treatment of pancreatic cancer remains a formidable challenge to clinicians. Here we describe the case of a 57-year-old man with metastatic pancreatic cancer who received combination treatment with cetuximab and capecitabine plus gemcitabine for four cycles. Repeat CT scan showed that the size of both the primary tumor in the pancreas and the metastatic lesions in the liver had shrunk significantly. Rapid reduction of the serum CA19-9 level was observed, and no serious toxic events occurred. The patient had a progression-free survival of eight months at the time we wrote this paper. The combination of cetuximab and capecitabine plus gemcitabine may be a useful therapy in metastatic pancreatic cancer. Free full text available at www.tumorionline.it
ParkinD.M., BrayF., FerlayJ., PisaniP.: Global cancer statistics, 2002. CA Cancer J Clin, 55: 74–108, 2005.
2.
KullmannF., HollerbachS., DollingerM.M., HarderJ., FuchsM., MessmannH., TrojanJ., GabeleE., HinkeA., HollerbachC., EndlicherE.: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer, 100: 1032–1036, 2009.
3.
SenerS.F., FremgenA., MenckH.R., WinchesterD.P.: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg, 189: 1–7, 1999.
4.
BurrisH.3rd, Rocha-LimaC.: New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist, 13: 289–298, 2008.
5.
BurrisH.A.3rd, MooreM.J., AndersenJ., GreenM.R., RothenbergM.L., ModianoM.R., CrippsM.C., PortenoyR.K., StornioloA.M., TarassoffP., NelsonR., DorrF.A., StephensC.D., Von HoffD.D.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15: 2403–2413, 1997.
6.
HerrmannR., BodokyG., RuhstallerT., GlimeliusB., BajettaE., SchullerJ., SalettiP., BauerJ., FigerA., PestalozziB., KohneC.H., MingroneW., StemmerS.M., TamasK., KornekG.V., KoeberleD., CinaS., BernhardJ., DietrichD., ScheithauerW.: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol, 25: 2212–2217, 2007.
7.
SultanaA., SmithC.T., CunninghamD., StarlingN., NeoptolemosJ.P., GhanehP.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol, 25: 2607–2615, 2007.
8.
CascinuS., BerardiR., LabiancaR., SienaS., FalconeA., AitiniE., BarniS., Di CostanzoF., DaprettoE., ToniniG., PierantoniC., ArtaleS., RotaS., FlorianiI., ScartozziM., ZaniboniA., Italian Group for the Study of Digestive Tract Cancer (GIS-CAD): Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol, 9: 39–44, 2008.
9.
PhilipP.A., BenedettiJ., Fenoglio-PreiserC., ZalupskiM., LenzH., O'ReillyE., WongR., AtkinsJ., AbruzzeseJ., BlankeC.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol, ASCO Annual Meeting Proceedings part 1, 25: LBA4509, 2007.
10.
SchönlebenF., AllendorfJ.D., QiuW., LiX., HoD.J., CiauN.T., FineR.L., ChabotJ.A., RemottiH.E., SuG.H.: Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas, 36: 168–172, 2008.
